Press release

Appointment of Eric Drapé as Executive Vice President, Manufacturing and Supply Organisation

Paris (France), 3 April 2007 – Ipsen (Euronext: FR0010259150; IPN) today announced the appointment with effect from 2nd May 2007, of Eric Drapé as Executive Vice-President, Manufacturing and Supply Organisation and member of Ipsen’s Executive Committee. This appointment is within the context of the retirement of Peter Wilson.

Peter Wilson will continue to work with the company in an advisory role providing consultative assistance on matters principally related to Ginkgo Biloba extract (EGb 761®) activities.

Eric Drapé, who is 45 years old, joins Ipsen having spent the prior 16 years at Novo Nordisk, serving since 2004 as Senior Vice President of the company’s Diabetes Finished Products division, responsible for 6 plants (in the USA, Brazil, France and Denmark) and 3,800 employees. Prior to this post, he was Vice President of Product Supply, at Chartres (France) and before that, Vice President of Quality International Operations and Quality Support. Eric Drapé completed his Doctorate in Pharmacy in 1986 at Université Paris XI, and finished his DESS (Analytical Control of Drugs) in 1987. He also received his MBA in 1999 from the Scandinavian International Management Institute in Copenhagen.

About Ipsen

Ipsen is an innovation driven international specialty pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,000. The company's development strategy is based on a combination of products in targeted therapeutic areas (oncology, endocrinology and neuromuscular disorders) which are growth drivers, and primary care products which contribute significantly to its research financing. This strategy is also supported by an active policy of partnerships. The location of its four Research and Development centres (Paris, Boston, Barcelona, London) gives the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. In 2006, R&D expenditure was €178.3 million, i.e. 20.7% of consolidated sales, which amounted to €861.7 million while total revenues amounted to €945.3 million (in IFRS). 700 people in R&D are dedicated to the discovery and development of innovative drugs for patient care. Ipsen’s shares are traded on Segment A of Eurolist by Euronext™ (stock code: IPN, ISIN code: FR0010259150). Ipsen’s shares are eligible to the “Système à Règlement Différé” (“SRD”) and the Group is part of the SBF 250 index. For more information on Ipsen, visit our website at www.ipsen.com.

Forward-looking statements

The forward-looking statements and targets contained herein are based on Ipsen's management's current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein.

Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable
law. Ipsen's business is subject to the risk factors outlined in its information documents filed with the French Autorité des marchés financiers.

For further information:
Didier Véron, Director, Public Affairs and Corporate Communications
Tel.: +33 (0)1 44 30 42 38 - Fax: +33 (0)1 44 30 42 04
E-mail: didier.veron@ipsen.com

David Schilansky, Investor Relations Officer
Tel.: +33 (0)1 44 30 43 31 - Fax: +33 (0)1 44 30 43 21
E-mail: david.schilansky@ipsen.com